The Medicines Patent Pool (MPP) welcomes an announcement by ViiV Healthcare that it is committed to licensing its patents for cabotegravir Long-Acting (LA) for HIV pre-exposure prophylaxis (PrEP).

MPP looks forward to negotiating and implementing a voluntary licence that will enable the development of generic versions of cabotegravir LA for PrEP to support access and scale-up in low- and middle-income countries.

“Because of its long-acting nature, cabotegravir is potentially a very important drug in our battle against HIV,” said Charles Gore, Executive Director of MPP.

“In particular, it could be a game-changer in prevention. It is critical that it becomes widely available to the people who could benefit from it. We are therefore delighted that ViiV has committed to working with us on a voluntary licence to contribute to making that possible,” Gore said.

Access ViiV Healthcare’s announcement

More on ViiV Healthcare